Enzo Grossi & Fabio Pace
doi : 10.1007/s10620-020-06634-3
Digestive Diseases and Sciences volume 66, pages2473–2474 (2021)
Aaron Shanker & Mohammad Bashashati
doi : 10.1007/s10620-020-06603-w
Digestive Diseases and Sciences volume 66, pages2475–2477 (2021)
Jason K. Hou
doi : 10.1007/s10620-020-06570-2
Digestive Diseases and Sciences volume 66, pages2478–2480 (2021)
Foong Way David Tai
doi : 10.1007/s10620-020-06604-9
Digestive Diseases and Sciences volume 66, pages2481–2482 (2021)
Norah A. Terrault & Marc G. Ghany
doi : 10.1007/s10620-020-06584-w
Digestive Diseases and Sciences volume 66, pages2483–2485 (2021)
Deborah D. Proctor
doi : 10.1007/s10620-021-07102-2
Digestive Diseases and Sciences volume 66, pages2486–2488 (2021)
Deborah D. Proctor
doi : 10.1007/s10620-021-07103-1
Digestive Diseases and Sciences volume 66, pages2489–2492 (2021)
Albert J. Czaja
doi : 10.1007/s10620-020-06562-2
Digestive Diseases and Sciences volume 66, pages2493–2512 (2021)
Interleukin 2 is essential for the expansion of regulatory T cells, and low-dose recombinant interleukin 2 has improved the clinical manifestations of diverse autoimmune diseases in preliminary studies. The goals of this review are to describe the actions of interleukin 2 and its receptor, present preliminary experiences with low-dose interleukin 2 in the treatment of diverse autoimmune diseases, and evaluate its potential as a therapeutic intervention in autoimmune hepatitis. English abstracts were identified in PubMed by multiple search terms. Full-length articles were selected for review, and secondary and tertiary bibliographies were developed. Interleukin 2 is critical for the thymic selection, peripheral expansion, induction, and survival of regulatory T cells, and it is also a growth factor for activated T cells and natural killer cells. Interleukin 2 activates the signal transducer and activator of transcription 5 after binding with its trimeric receptor on regulatory T cells. Immune suppressor activity is increased; anti-inflammatory interleukin 10 is released; pro-inflammatory interferon-gamma is inhibited; and activation-induced apoptosis of CD8+ T cells is upregulated. Preliminary experiences with cyclic injections of low-dose recombinant interleukin 2 in diverse autoimmune diseases have demonstrated increased numbers of circulating regulatory T cells, preserved regulatory function, improved clinical manifestations, and excellent tolerance. Similar improvements have been recognized in one of two patients with refractory autoimmune hepatitis. In conclusion, interferon 2 has biological actions that favor the immune suppressor functions of regulatory T cells, and low-dose regimens in preliminary studies encourage its rigorous investigation in autoimmune hepatitis.
Shubha Bhat, Jimmy K. Limdi, Raymond K. Cross & Francis A. Farraye
doi : 10.1007/s10620-021-07114-y
Digestive Diseases and Sciences volume 66, pages2513–2532 (2021)
The introduction of therapeutic monoclonal antibodies directed against tumor necrosis factor-? has revolutionized the treatment of inflammatory bowel disease (IBD) by improving quality of life, decreasing the frequency and length of hospital admissions, and reducing corticosteroid use. Nevertheless, biologics are very expensive, substantially contributing to the cost of care for patients with IBD. To reduce this cost and improve treatment access, biosimilars, which are therapeutic monoclonal antibodies (biologicals) similar to but not identical to the reference biologic, were introduced. Despite their potential benefits, the adoption and uptake of biosimilars have varied considerably across the USA and Europe. Here, we highlight the current biosimilar therapeutic landscape, discuss barriers to their use, and provide an overview of published studies evaluating the efficacy and safety of biosimilars in IBD.
Maria Chiara Cianci, Riccardo Coletta & Antonino Morabito
doi : 10.1007/s10620-021-07071-6
Digestive Diseases and Sciences volume 66, pages2533–2536 (2021)
In the setting of intermittent abdominal pain accompanied by gastro-intestinal obstruction, gastric volvulus should be suspected.
Maria Chiara Cianci
doi : 10.1007/s10620-021-07072-5
Digestive Diseases and Sciences volume 66, page2537 (2021)
Irmina A. Elliott, Erna Forg? & Natalie S. Lui
doi : 10.1007/s10620-020-06703-7
Digestive Diseases and Sciences volume 66, pages2538–2541 (2021)
Barnabas Yik & Nimeesh Shah
doi : 10.1007/s10620-020-06768-4
Digestive Diseases and Sciences volume 66, pages2542–2544 (2021)
John W. Blackett, Nikhil A. Kumta, Rebekah E. Dixon, Yakira David, Satish Nagula, Christopher J. DiMaio, David Greenwald, Reem Z. Sharaiha, Kartik Sampath, David Carr-Locke, Arcelia Guerson-Gil, Sammy Ho, Benjamin Lebwohl, Reuben Garcia-Carrasquillo, Anjana Rajan, Vasantham Annadurai, Tamas A. Gonda, Daniel E. Freedberg & Srihari Mahadev
doi : 10.1007/s10620-020-06593-9
Digestive Diseases and Sciences volume 66, pages2545–2554 (2021)
The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the practice of endoscopy, but characteristics of COVID patients undergoing endoscopy have not been adequately described.
Hanna Blaney, Peter Vu, Antony Mathew, Robin Snelling, Julie England, Camille Duong, Kendall Hammonds & Christopher Johnson
doi : 10.1007/s10620-020-06590-y
Digestive Diseases and Sciences volume 66, pages2555–2563 (2021)
Anemia is a common systemic complication of inflammatory bowel disease (IBD) and is associated with worse disease outcomes, quality of life, and higher healthcare costs.
Maria Barsky, Joseph Meserve, Helen Le, Angelina Collins, Siddharth Singh, Brigid Boland, William J. Sandborn & Parambir S. Dulai
doi : 10.1007/s10620-020-06568-w
Digestive Diseases and Sciences volume 66, pages2564–2569 (2021)
Evidence is now available in support of using fecal biomarkers to monitor disease activity in inflammatory bowel disease (IBD). Patient adherence is often cited as a barrier to implementation. We assessed patient determinants for using stool tests to monitor disease activity.
Nicole G. Jawitz, Ziad F. Gellad, Li Lin, Richard K. Wood & David A. Leiman
doi : 10.1007/s10620-020-06592-w
Digestive Diseases and Sciences volume 66, pages2570–2577 (2021)
Variability in colon polyp detection impacts patient outcomes. However, the relative influence of physician, patient, and procedure-specific factors on polyp detection is unclear. Therefore, determining how these factors contribute to adenoma and sessile serrated polyp (SSP) detection is important to contextualize measures of colonoscopy quality such as adenoma detection rate and patient outcomes.
Alexander Hua Xiao, Stephen Y. Chang, Christian G. Stevoff, Srinadh Komanduri, John E. Pandolfino & Rajesh N. Keswani
doi : 10.1007/s10620-020-06539-1
Digestive Diseases and Sciences volume 66, pages2578–2584 (2021)
COVID-19 has caused a backlog of endoscopic procedures; colonoscopy must now be prioritized to those who would benefit most. We determined the proportion of screening and surveillance colonoscopies appropriate for rescheduling to a future year through strict adoption of US Multi-Society Task Force (USMSTF) guidelines.
Abbinaya Elangovan, Jacob Skeans, Ishan Lalani, Farhan Ullah, Aparna Roy, David C. Kaelber, Gregory S. Cooper & Dalbir S. Sandhu
doi : 10.1007/s10620-020-06545-3
Digestive Diseases and Sciences volume 66, pages2585–2594 (2021)
Although colorectal cancer screening (CRC) using stool-based test is well-studied, evidence on fecal immunochemical test (FIT) patterns in a safety-net healthcare system utilizing opportunistic screening is limited. We studied the FIT completion rates and adenoma detection rate (ADR) of positive FIT-colonoscopy (FIT-C) in an urban safety-net system.
Harry Trieu, Arpan Patel, Christine Wells, Sammy Saab & Edward Wolfgang Lee
doi : 10.1007/s10620-020-06582-y
Digestive Diseases and Sciences volume 66, pages2595–2602 (2021)
Hepatic encephalopathy (HE) is a common cause of hospitalizations and readmissions for patients with decompensated cirrhosis. In this study, we proposed to investigate recent trends in in-hospital mortality and utilization for patients with cirrhosis and HE and to explore the effect of various sociodemographic, hospital, and clinical factors on mortality.
Jawaid Shaw, Kavish R. Patidar, Bradley Reuter, Navid Hajezifar, Narayan Dharel, James B. Wade & Jasmohan S. Bajaj
doi : 10.1007/s10620-020-06583-x
Digestive Diseases and Sciences volume 66, pages2603–2609 (2021)
Health education interventions are successful in modifying lifestyle. Functional health literacy (FHL) can determine patient adherence to clinic visits and procedures and may adversely impact the success of these interventions.
Sandro da Costa Ferreira, Ibrahim Abiodoun Sadissou, Rogério Serafim Parra, Marley Ribeiro Feitosa, Fermino Sanches Lizarte Neto, Daniela Pretti da Cunha Tirapelli, Leandra Naira Zambelli Ramalho, Omar Féres, José Joaquim Ribeiro da Rocha, Eduardo Antônio Donadi & Luiz Ernesto de Almeida Troncon
doi : 10.1007/s10620-020-06561-3
Digestive Diseases and Sciences volume 66, pages2610–2618 (2021)
Since HLA-G is an immune checkpoint molecule and since Crohn’s disease (CD) and ulcerative colitis (UC) exhibit deregulated immune-mediated mechanisms, we aimed to evaluate intestinal HLA-G expression and soluble HLA-G (sHLA-G) levels in CD/UC patients stratified according to the CD phenotype/localization and UC extension.
Michael Shpoliansky, Dirk Roggenbuck, Marina Pinsker, Naomi Salamon, Batia Weiss, Dror S. Shouval & Lael Werner
doi : 10.1007/s10620-020-06589-5
Digestive Diseases and Sciences volume 66, pages2619–2626 (2021)
Serological markers can assist in accurate differentiation between Crohn’s disease (CD) and ulcerative colitis (UC). One such marker is anti-glycoprotein 2 (anti-GP2) which was shown to be a specific marker for CD in adult patients. The aim of our study was to assess the utility of anti-GP2 and GP2 as biomarkers for pediatric CD, and determine whether they correlate with disease activity.
Xiu Yuan, Tianwen Yang, Yun Xu, Shan Ou, Peng Shi, Ming Cao, Xin Zuo, Qinglan Liu & Jie Yao
doi : 10.1007/s10620-020-06576-w
Digestive Diseases and Sciences volume 66, pages2627–2636 (2021)
Long non-coding RNAs have been acknowledged as the crucial regulators in the progression of human cancers, including gastric cancer (GC). Small nucleolar RNA host gene 10 (SNHG10) has been identified as an oncogene in several cancer types. Nonetheless, it is unclear whether SNHG10 exerts functions in GC cells.
Yejia Cui, Rong Pu, Jinjun Ye, Haohai Huang, Dan Liao, Yufeng Yang, Wanchan Chen, Yelin Yao & Yingai He
doi : 10.1007/s10620-020-06581-z
Digestive Diseases and Sciences volume 66, pages2637–2650 (2021)
Long non-coding RNAs serve as key components of competing endogenous RNA (ceRNA) networks that underlie tumorigenesis. We investigated the pathogenic roles of lncRNA FAM230B and its molecular mechanism in gastric cancer (GC).
Li Zhang, Heping Chen, Yueqiong Song, Qing Gu, Lu Zhang, Qin Xie, Jin Xu & Min Zhang
doi : 10.1007/s10620-020-06579-7
Digestive Diseases and Sciences volume 66, pages2651–2660 (2021)
Oxaliplatin is one of the most effective chemotherapeutic drugs used for the treatment of colorectal cancer (CRC). However, intervention that attenuates the resistance of oxaliplatin is still required in the treatment of CRC.
Aleksandr Birg, Henry C. Lin & Nancy Kanagy
doi : 10.1007/s10620-020-06597-5
Digestive Diseases and Sciences volume 66, pages2661–2668 (2021)
Hydrogen sulfide (H2S) is a recently discerned endogenous signaling molecule that modulates the vascular system. Endogenous hydrogen sulfide has been shown to dilate both the mesenteric and portal vasculature. Gut microbiome, via sulfur reducing bacteria, is another source of H2S production within the gut lumen; this source of H2S is primarily produced and detoxified in the colon under physiologic conditions. Nitric oxide (NO), a major endogenous vasodilator in the portal circulation, participates in H2S-induced vasodilation in some vascular beds. We hypothesize that jejunal but not colonic H2S increases portal vein flow in a NO-dependent fashion. To evaluate the effects of luminal H2S, venous blood flow, portal venous pressure, and systemic venous pressure were measured in rats after administration of either vehicle or an H2S donor (NaHS) into the jejunum or the colon. We found that portal venous pressure and systemic pressure did not change and were similar between the three study groups. However, portal venous blood flow significantly increased following jejunal administration of NaHS but not in response to colonic NaHS or vehicle administration. To test the contribution of NO production to this response, another group of animals was treated with either an NO synthase inhibitor (N-?-nitro-L-arginine, L-NNA) or saline prior to jejunal NaHS infusion. After L-NNA pretreatment, NaHS caused a significant fall rather than increase in portal venous flow compared to saline pretreatment. These data demonstrate that H2S within the small intestine significantly increases portal venous blood flow in a NO-dependent fashion.
Mohammad Maysara Asfari, Katherine Kendrick, Muhammad Talal Sarmini, Pearl Uy & Kenneth J. Vega
doi : 10.1007/s10620-020-06566-y
Digestive Diseases and Sciences volume 66, pages2669–2673 (2021)
Eosinophilic esophagitis (EoE) is thought to be an atopic disorder causing dysphagia. HIV patients have dysphagia from both common (reflux esophagitis) and uncommon causes (idiopathic esophageal ulceration). Only a single case report about the occurrence of EoE in an HIV patient exists in literature.
Kentaro Ishikawa, Kenichiro Okimoto, Tomoaki Matsumura, Yosuke Hirotsu, Kenji Amemiya, Takashi Kishimoto, Naoki Akizue, Yuki Ohta, Keiko Saito, Daisuke Maruoka, Motoi Nishimura, Kazuyuki Matsushita, Hitoshi Mochizuki, Makoto Arai, Jun Kato, Osamu Yokosuka, Masao Omata & Naoya Kato
doi : 10.1007/s10620-020-06563-1
Digestive Diseases and Sciences volume 66, pages2674–2681 (2021)
Barrett’s esophagus (BE) is a precursor of esophageal adenocarcinoma (EAC). Therefore, an accurate diagnosis of BE is important for the subsequent follow-up and early detection of EAC. However, the definitions of BE have not been standardized worldwide; columnar-lined epithelium (CLE) without intestinal metaplasia (IM) and/or <?1 cm is not diagnosed as BE in most countries. This study aimed to clarify the malignant potential of CLE without IM and/or <?1 cm genetically.
Asad Jehangir, Zubair Malik, Roman V. Petrov & Henry P. Parkman
doi : 10.1007/s10620-020-06510-0
Digestive Diseases and Sciences volume 66, pages2682–2690 (2021)
Gastroparesis patients may undergo pyloromyotomy/pyloroplasty for chronic refractory symptoms. However, some patients have persistent symptoms. It is unknown if balloon dilation may improve their symptoms.
Motasem Alkhayyat, Mohannad Abou Saleh, Mohammad Abureesh, George Khoudari, Thabet Qapaja, Emad Mansoor, C. Roberto Simons-Linares, John Vargo, Tyler Stevens, Alberto Rubio-Tapia & Prabhleen Chahal
doi : 10.1007/s10620-020-06546-2
Digestive Diseases and Sciences volume 66, pages2691–2699 (2021)
Celiac disease (CD) is a chronic immune-mediated enteropathy that is precipitated by dietary gluten in genetically predisposed individuals. A few studies reported a higher incidence of pancreatitis in the CD population. Using a large US database, we sought to describe the epidemiology, risk, and outcomes of acute pancreatitis (AP) and chronic pancreatitis (CP) in CD patients.
Jonathan M. Rhodes, Sreedhar Subramanian, Paul K. Flanagan, Graham W. Horgan, Kate Martin, John Mansfield, Miles Parkes, Ailsa Hart, Helen Dallal, Tariq Iqbal, Jeffrey Butterworth, Kate Culshaw & Christopher Probert
doi : 10.1007/s10620-020-06477-y
Digestive Diseases and Sciences volume 66, pages2700–2711 (2021)
Increased mucosa-associated E. coli are present in Crohn’s disease, but their role in pathogenesis is uncertain.
Thomas Chateau, Ferdinando Damico, Camille Zallot, Nicolas Mathieu & Laurent Peyrin-Biroulet
doi : 10.1007/s10620-020-06553-3
Digestive Diseases and Sciences volume 66, pages2712–2716 (2021)
In rare cases, the diagnosis of Crohn’s disease (CD) can only be achieved using small bowel capsule endoscopy (SBCE). We investigate the characteristics of patients with CD only visible on SBCE and assess their disease course.
Joshua Y. Kwon, Alex M. Kesler, Herbert C. Wolfsen, Kenneth R. DeVault & Paul T. Kr?ner
doi : 10.1007/s10620-020-06559-x
Digestive Diseases and Sciences volume 66, pages2717–2723 (2021)
Patients with Barrett’s esophagus (BE) are more likely to have associated hiatal hernia (HH) compared to the general population. Studies show that HH are typically longer and wider in patients with BE.
Sang Pyo Lee, Jin Lee, Sea Hyub Kae, Hyun Joo Jang & Eun Suk Jung
doi : 10.1007/s10620-020-06511-z
Digestive Diseases and Sciences volume 66, pages2724–2731 (2021)
Currently, because the population is aging, use of medications has been increasing, including use of nonsteroidal anti-inflammatory drugs (NSAIDs) and antithrombotic agents.
Remo Panaccione, John D. Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Wang, Gary Chan & Chinyu Su
doi : 10.1007/s10620-020-06560-4
Digestive Diseases and Sciences volume 66, pages2732–2743 (2021)
Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Creatine kinase (CK) levels and CK-related adverse events (AEs) in tofacitinib-treated patients with UC were evaluated.
Stephane Paul, Nicolas Williet, Stéphane Nancey, Pauline Veyrard, Gilles Boschetti, Jean-Marc Phelip, Bernard Flourie & Xavier Roblin
doi : 10.1007/s10620-020-06567-x
Digestive Diseases and Sciences volume 66, pages2744–2749 (2021)
The pharmacokinetic equivalence of dose intensification with adalimumab (ADA) 80 mg every other week (EOW) compared to weekly 40 mg has only been supported by modeling systems.
Fatma Alibaz-Oner, Rabia Ergelen, Ilkay Ergenc, Gizem Seven, Ayten Yaz?c?, Ayse Cefle, Cemal Bes, Ozlen Atug & Haner Direskeneli
doi : 10.1007/s10620-020-06587-7
Digestive Diseases and Sciences volume 66, pages2750–2755 (2021)
Behçet’s disease (BD) and Crohn’s disease (CD) cannot be easily differentiated in young adults presenting with nonspecific gastrointestinal (GI) manifestations due to similar extraintestinal manifestations. We recently showed that increased common femoral vein (CFV) thickness is a distinctive feature of BD, rarely present in other inflammatory or vascular diseases with a specificity higher than 80% for the cutoff value of???0.5 mm. We suggest that CFV thickness measurement with ultrasonography (US) can be a diagnostic tool for BD.
Jong Yoon Lee, Myeongseok Koh & Jong Hoon Lee
doi : 10.1007/s10620-020-06543-5
Digestive Diseases and Sciences volume 66, pages2756–2762 (2021)
Adenoma detection rate (ADR) is an important quality indicator of colonoscopy. High-definition (HD) colonoscopy has been reported to increase ADR compared to standard-definition (SD) colonoscopy. Although there are few reports comparing the latest generation and the previous generation of HD colonoscopy equipment, there are reports that the latest generation colonoscopy equipment improves ADR. However, there are no reports on the impact of the latest generation HD colonoscopy on the ADR of trainee endoscopists.
Linbin Chen, Yin Li, Xiaoyan Gao, Shiyong Lin, Longjun He, Guangyu Luo, Jianjun Li, Chunyu Huang, Guobao Wang, Qing Yang & Hongbo Shan
doi : 10.1007/s10620-020-06554-2
Digestive Diseases and Sciences volume 66, pages2763–2775 (2021)
Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is increasingly being used for diagnosing lymphadenopathy. We aim to systematically review the accuracy of EUS-FNA in differentiating benign and malignant mediastinal and abdominal lymph nodes (LNs).
Matthew R. Krafft, Wei Fang & John Y. Nasr
doi : 10.1007/s10620-020-06551-5
Digestive Diseases and Sciences volume 66, pages2776–2785 (2021)
EUS-directed transgastric ERCP (EDGE) is an endoscopic modality for treating pancreaticobiliary disorders after Roux-en-Y gastric bypass. EDGE consists of EUS-directed gastrogastrostomy/jejunogastrostomy creation (EUS-GG; step 1), followed by transgastric ERCP (step 2). The two steps can be performed in the same or separate endoscopic session(s). Single-session EDGE is immediately therapeutic but risks perforation via LAMS dislodgement. Dual-session EDGE does not risk perforation, but the clinical malady festers during the 10–14-day interval required for fistula maturation. A “shortened-interval dual-session” EDGE (2–4 day interval) may resolve this dilemma. Our study compares 20-mm LAMS dislodgement risk between single-session and shortened-interval dual-session EDGE.
Tugrul Purnak, Ihab I. El Hajj, Stuart Sherman, Evan L. Fogel, Lee McHenry, Glen Lehman, Mark A. Gromski, Mohammad Al-Haddad, John DeWitt, James L. Watkins & Jeffrey J. Easler
doi : 10.1007/s10620-020-06564-0
Digestive Diseases and Sciences volume 66, pages2786–2794 (2021)
A single-procedure session combining EUS and ERCP (EUS/ERCP) for tissue diagnosis and biliary decompression for pancreatic duct adenocarcinoma (PDAC) is technically feasible. While EUS/ERCP may offer expedience and convenience over an approach of separate procedures sessions, the technical success and risk for complications of a combined approach is unclear.
C. Roberto Simons-Linares, Suha Abushamma, Carlos Romero-Marrero, Amit Bhatt, Rocio Lopez, Sunguk Jang, John Vargo, Tyler Stevens, Robert O’Shea, William Carey & Prabhleen Chahal
doi : 10.1007/s10620-020-06575-x
Digestive Diseases and Sciences volume 66, pages2795–2804 (2021)
Literature on acute pancreatitis (AP) outcomes in patients with cirrhosis is limited. We aim to investigate the mortality and morbidity of AP in patients with cirrhosis.
Hiroaki Nozawa, Shigenobu Emoto, Hirofumi Sonoda, Kazushige Kawai, Kazuhito Sasaki, Manabu Kaneko, Koji Murono, Hiroaki Ishii & Soichiro Ishihara
doi : 10.1007/s10620-020-06586-8
Digestive Diseases and Sciences volume 66, pages2805–2815 (2021)
Enoxaparin, a low molecular weight heparin, has been used to prevent thrombotic events during major surgery without increasing the rate of hemorrhage. On the other hand, it was reported to cause liver injury, but the details of liver injury induced by prophylactic enoxaparin after abdominal surgery remain unclear.
Joo Hyun Oh, Myung Ji Goh, Yewan Park, Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik & Yong-Han Paik
doi : 10.1007/s10620-020-06591-x
Digestive Diseases and Sciences volume 66, pages2816–2825 (2021)
Liver stiffness measurement (LSM) by transient elastography (TE) has shown promising results for prediction of hepatocellular carcinoma (HCC) and hepatic decompensation in patients with chronic liver disease (CLD). However, whether prognostic performance of TE differs according to etiology or type of outcome remains further clarification.
Carlos Ferre-Aracil, Mar Riveiro-Barciela, Mar?a Trapero-Marug?n, Manuel Rodr?guez-Per?lvarez, Laura-Patricia Llovet, Luis Téllez, Yolanda S?nchez-Torrijos, Fernando D?az-Fontenla, Magdalena Salcedo-Plaza, Patricia ?lvarez-L?pez, Manuel de la Mata, Mar?a-Carlota Londo?o, Rafael Ba?ares-Ca?izares & José Luis Calleja
doi : 10.1007/s10620-020-06569-9
Digestive Diseases and Sciences volume 66, pages2826–2832 (2021)
Autoimmune hepatitis (AIH) is a chronic liver disease able to progress to acute liver failure, cirrhosis, and liver cancer. A significant proportion of patients fail to first-line therapy or develop severe toxicity.
Tse-Ling Fong, Brian T. Lee, Mimi Chang, Khishigsuren Nasanbayar, Enkhjargal Tsogtoo, Delgerbat Boldbaatar, Esugen D. Dashdorj, Namuun E. Clifford, Arghun N. Dashdorj, Bo-Ram Bang, Takeshi Chida, Carolina Lim, Masaya Sugiyama, Masashi Mizokami, Naranjargal J. Dashdorj, Ping Liu, Jeffrey S. Glenn, Naranbaatar D. Dashdorj & Takeshi Saito
doi : 10.1007/s10620-020-06499-6
Digestive Diseases and Sciences volume 66, pages2833–2839 (2021)
Mongolia is a highly endemic region for chronic hepatitis B (HBV), hepatitis delta (HDV), and hepatitis C (HCV) infections. Aim of this study was to comprehensively characterize chronic viral hepatitis among Mongols living in Southern California.
Rogério Serafim Parra, José Joaquim Ribeiro da Rocha & Omar Féres
doi : 10.1007/s10620-021-07091-2
Digestive Diseases and Sciences volume 66, pages2840–2841 (2021)
Yamini Natarajan, Aylin Tansel, Parth Patel, Ikenna K. Emelogu, Richa Shukla, Zeeshan Qureshi, Hashem B. El?Serag, Aaron P. Thrift & Fasiha Kanwal
doi : 10.1007/s10620-020-06619-2
Digestive Diseases and Sciences volume 66, page2842 (2021)
Jessica Atieh, Jordan Sack, Richard Thomas, Osama E. Rahma, Michael Camilleri & Shilpa Grover
doi : 10.1007/s10620-020-06515-9
Digestive Diseases and Sciences volume 66, pages2843–2844 (2021)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟